STABILITY INDICATING HPLC METHOD FOR THE DETERMINATION OF ESLICARBAZEPINE ACETATE AND ITS IMPURITIES IN BULK DRUGS AND PHARMACEUTICAL DOSAGE FORMS
- 22 June 2012
- journal article
- research article
- Published by Taylor & Francis in Journal of Liquid Chromatography & Related Technologies
- Vol. 35 (11) , 1550-1564
Abstract
A new stability-indicating gradient reverse phase high-performance liquid chromatographic (RP-HPLC) method was developed for the quantitative determination of Eslicarbazepine acetate (antiepileptic drug) in bulk drugs and pharmaceutical dosage forms along with its impurities and degradation products. The method was developed using Zorbax SB C-18 (150 mm × 4.6 mm, 3.5 µm) column with mobile phase containing a gradient mixture of solvents A and B. The solvent A contains a mixture of 0.01 M KH2PO4 and Methanol in the ratio of 80:20, and the solvent B contains a mixture of Acetonitrile, Methanol, and Water in the ratio 75:5:20 (v/v). Eslicarbazepine acetate was subjected to the stress conditions of oxidative degradation, acid, base, neutral hydrolysis, and thermal and photolytic degradation. Eslicarbazepine acetate was found to degrade significantly in acid, base, neutral hydrolysis, and oxidative stress conditions. The degradation products were well resolved from main peak and its impurities within 20 min run time, proving the stability-indicating power of the method. The developed method was validated as per International Conference on Harmonization (ICH) guidelines with respect to specificity, linearity, accuracy, precision, and robustness. This method was also suitable for the assay determination of Eslicarbazepine acetate in drug substance and drug product.Keywords
This publication has 9 references indexed in Scilit:
- Development of liquid chromatographic enantiomer separation methods and validation for the estimation of (R)-enantiomer in eslicarbazepine acetateJournal of Pharmaceutical and Biomedical Analysis, 2011
- Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasmaAnalytical and Bioanalytical Chemistry, 2010
- Key factors in the discovery and development of new antiepileptic drugsNature Reviews Drug Discovery, 2010
- Simultaneous and enantioselective liquid chromatographic determination of eslicarbazepine acetate, S-licarbazepine, R-licarbazepine and oxcarbazepine in mouse tissue samples using ultraviolet detectionAnalytica Chimica Acta, 2007
- Eslicarbazepine Acetate (BIA 2-093)Neurotherapeutics, 2007
- Single‐Dose and Steady‐State Pharmacokinetics of Eslicarbazepine Acetate (BIA 2–093) in Healthy Elderly and Young SubjectsThe Journal of Clinical Pharmacology, 2005
- Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)Epilepsy Research, 2004
- The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepineNeurochemistry International, 2002
- Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(−)-10,11-dihydro-10-hydroxy carbamazepineEpilepsy Research, 2001